Latest news with #Organon&Co
Yahoo
11-07-2025
- Business
- Yahoo
Organon & Co. (OGN) Announces American Academy of Dermatology's Strong Recommendation for VTAMA Cream
Organon & Co. (NYSE:OGN) is one of the . On July 7, Organon & Co. (NYSE:OGN) announced that its VTAMA (tapinarof) cream, 1%, attained a strong recommendation in the American Academy of Dermatology's (AAD) 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD). A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy. Organon & Co. (NYSE:OGN) stated that the recommendation highlights the cream's status as a steroid-free and effective option for daily disease management. It does not have precautions or label warnings, no restrictions on use duration or percentage of body surface area affected, and no contraindications. Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women's health, established brands, and biosimilars. While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program
Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet its primary efficacy endpoint. The study evaluated the investigational candidate OG-6219 in endometriosis-related pain, with OG-6219 being an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor. A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy. Organon & Co. (NYSE:OGN) acquired OG-6219 through its 2021 acquisition of Forendo Pharma. The compound did not exhibit improvement in moderate-to-severe endometriosis-related overall pelvic pain in the study as compared to the placebo, which is why Organon & Co. (NYSE:OGN) plans to discontinue the clinical development program. Juan Camilo Arjona Ferreira, M.D., Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), stated that while the study results were disappointing, the company remains committed to its focus on improving the lives of women with endometriosis. Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women's health, established brands, and biosimilars. While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
10-07-2025
- Business
- Yahoo
Organon & Co. (OGN) Announces Discontinuation of the OG-6219 Clinical Development Program
Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet its primary efficacy endpoint. The study evaluated the investigational candidate OG-6219 in endometriosis-related pain, with OG-6219 being an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor. A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy. Organon & Co. (NYSE:OGN) acquired OG-6219 through its 2021 acquisition of Forendo Pharma. The compound did not exhibit improvement in moderate-to-severe endometriosis-related overall pelvic pain in the study as compared to the placebo, which is why Organon & Co. (NYSE:OGN) plans to discontinue the clinical development program. Juan Camilo Arjona Ferreira, M.D., Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), stated that while the study results were disappointing, the company remains committed to its focus on improving the lives of women with endometriosis. Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women's health, established brands, and biosimilars. While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
08-07-2025
- Business
- Business Wire
EXTENDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Organon & Co. and Announces Opportunity for Investors with Substantial Losses to Lead the Organon Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, inclusive (the 'Class Period'). Captioned Lerner v. Organon & Co., No. 25-cv-12983 (D.N.J.), the Organon class action lawsuit charges Organon and certain of Organon's top executives with violations of the Securities Exchange Act of 1934. A previously filed complaint is captioned Hauser v. Organon & Co. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or of Robbins Geller by calling 800/449-4900 or via e-mail at info@ Lead plaintiff motions for the Organon class action lawsuit must be filed with the court no later than Tuesday, July 22, 2025. CASE ALLEGATIONS: Organon develops and delivers health solutions through prescription therapies and medical devices. The Organon class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Organon faced a higher risk of loss of exclusivity and price erosion as to Nexplanon than implied by its Class Period statements; (ii) as a result, Organon's long-term Nexplanon sales growth was not as strong as defendants' portended during the Class Period, and would not reach $1 billion by the end of fiscal year 2025 (much less upwards of $1.5 billion after that), and that Organon was likely not on track to achieve the $1 billion milestone payment from Merck & Co. on its Nexplanon sales thereafter; (iii) thus, Organon was not on track to achieve, much less maintain, the $1 billion in free cash flow required to sustain its outsized dividend; (iv) consequently, Organon was also not on track to maintain 4.0x debt leverage; (v) as such, Organon might not be able to maintain its corporate debt ratings at their then-current Class Period levels; and (vi) as a result, Organon lacked a reasonable basis to report its Class Period business metrics and financial projections. The Organon class action lawsuit further alleges that on May 1, 2025, in connection with announcing its first quarter 2025 financial results for the interim period ended March 31, 2025, Organon slashed its dividend by 90%, down from 28¢ per share per quarter ($1.16 per share annually) down to just 2¢ per share per quarter (or 8¢ per share annually). According to a quote attributed to Organon's CEO, defendant Kevin Ali, in the press release Organon issued that day, it had 'reset [its] capital allocation priorities to accelerate progress towards deleveraging, enabling a path to achieve a net leverage ratio of below 4.0x by year-end,' emphasizing that Organon's 'primary capital allocation priority' was now 'maintaining lower leverage.' On this news, the price of Organon stock fell more than 27%. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Organon publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Organon class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Organon class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Organon class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Organon class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
07-07-2025
- Business
- Yahoo
With 79% ownership of the shares, Organon & Co. (NYSE:OGN) is heavily dominated by institutional owners
Significantly high institutional ownership implies Organon's stock price is sensitive to their trading actions A total of 16 investors have a majority stake in the company with 51% ownership Insiders have bought recently We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Organon & Co. (NYSE:OGN) should be aware of the most powerful shareholder groups. With 79% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. In the chart below, we zoom in on the different ownership groups of Organon. See our latest analysis for Organon Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. Organon already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Organon's earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Organon is not owned by hedge funds. BlackRock, Inc. is currently the largest shareholder, with 12% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 11% and 4.1%, of the shares outstanding, respectively. A closer look at our ownership figures suggests that the top 16 shareholders have a combined ownership of 51% implying that no single shareholder has a majority. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our information suggests that Organon & Co. insiders own under 1% of the company. Keep in mind that it's a big company, and the insiders own US$9.6m worth of shares. The absolute value might be more important than the proportional share. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling. With a 20% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Organon. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Organon (of which 1 is potentially serious!) you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
